<p>Ferroptosis inhibitors alleviate <i>S. aureus</i>-induced cytotoxicity and oxidative damage in MAC-T cells.</p>

<p><b>(A)</b> LDH release from MAC-T cells infected with <i>S. aureus</i> ATCC25923 strain at different MOIs for 6 h (n = 5). <b>(B)</b> LDH release from MAC-T cells infected with ATCC25923 (MOI = 200) for the indicated times (n = 5). <b>(C)</b> LDH release from MAC-T cells treated with the indicated concentrations of erastin for 6 h (n = 5). <b>(D)</b> LDH release from MAC-T cells treated with 30 μM Erastin for 0, 6, 12, and 24 h (n = 5). <b>(E)</b> Schematic diagram of the experimental protocol for ferroptosis inhibitor intervention in <i>S. aureus</i>-infected MAC-T cells. <b>(F-J)</b> LDH release from MAC-T cells infected with <i>S. aureus</i> ATCC25923 strain (MOI = 200) in the presence of the indicated concentrations (0-30 μM) of ferrostatin-1 <b>(F)</b>, zileuton <b>(G)</b>, troglitazone <b>(H)</b>, TEMPO <b>(I)</b>, or deferiprone (J) for 6 h (n = 5). <b>(K-N)</b> Representative fluorescence images and (O-R) corresponding quantitative analyses of intracellular ROS (DCFH-DA; <b>K</b>, <b>O)</b>, Fe²⁺ accumulation <b>(L, P)</b>, lipid peroxidation (C11 BODIPY 581/591; <b>M</b>, <b>Q)</b>, and mitochondrial membrane potential (JC-10; N, R) in MAC-T cells subjected to <i>S. aureus</i> infection (MOI = 200), erastin treatment, or deferiprone intervention for the indicated durations (n = 3).

Scale bars, 200 μm. Data are presented as mean ± SD. *<i>P</i> < 0.05; **<i>P</i> < 0.01.</p>